Search hospitals > Nebraska > Lincoln
Southeast Nebraska Cancer Center - 68th Street Place
Claim this profileLincoln, Nebraska 68516
Global Leader in Lung Cancer
Global Leader in Parotid Gland Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Plasma Cell Neoplasm
95 reported clinical trials
4 medical researchers
Summary
Southeast Nebraska Cancer Center - 68th Street Place is a medical facility located in Lincoln, Nebraska. This center is recognized for care of Lung Cancer, Parotid Gland Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Plasma Cell Neoplasm and other specialties. Southeast Nebraska Cancer Center - 68th Street Place is involved with conducting 95 clinical trials across 184 conditions. There are 4 research doctors associated with this hospital, such as Ralph Hauke, MD, Joni A. Tilford, Mark J. Stavas, and Steve Dunder, MD.Area of expertise
1Lung Cancer
Global LeaderStage II
Stage IV
Stage I
2Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Ralph Hauke, MDNebraska Cancer Specialists2 years of reported clinical research
Expert in Prostate Cancer
Studies Prostatic Neoplasm
36 reported clinical trials
74 drugs studied
Joni A. TilfordCancer Partners of Nebraska - Pine Lake5 years of reported clinical research
Studies Parotid Gland Cancer
Studies Lung Cancer
21 reported clinical trials
49 drugs studied
Mark J. StavasSoutheast Nebraska Cancer Center - 68th Street Place6 years of reported clinical research
Studies Breast Cancer
Studies Prostate Cancer
5 reported clinical trials
17 drugs studied
Steve Dunder, MDSoutheast Nebraska Cancer Center5 years of reported clinical research
Studies Cystic Tumor
Studies Lymphoma
1 reported clinical trial
1 drug studied
Clinical Trials running at Southeast Nebraska Cancer Center - 68th Street Place
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Parotid Gland Cancer
Squamous Cell Carcinoma
Breast Cancer
Laryngeal Cancer
Melanoma
Cutaneous Melanoma
Skin Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Southeast Nebraska Cancer Center - 68th Street Place?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.